These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2259752)

  • 1. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development.
    Voisin EM; Ruthsatz M; Collins JM; Hoyle PC
    Regul Toxicol Pharmacol; 1990 Oct; 12(2):107-16. PubMed ID: 2259752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interspecies extrapolation of pharmacokinetics.
    Travis CC; White RK; Ward RC
    J Theor Biol; 1990 Feb; 142(3):285-304. PubMed ID: 2338826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapolation of animal toxicity data to man.
    Vocci F; Farber T
    Regul Toxicol Pharmacol; 1988 Dec; 8(4):389-98. PubMed ID: 3222480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interspecies extrapolation.
    Kenyon EM
    Methods Mol Biol; 2012; 929():501-20. PubMed ID: 23007441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A physiologically-based pharmacokinetic model for predicting doxorubicin disposition in multiple tissue levels and quantitative toxicity assessment.
    Chao FC; Manaia EB; Ponchel G; Hsieh CM
    Biomed Pharmacother; 2023 Dec; 168():115636. PubMed ID: 37826938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interspecies scaling and comparisons in drug development and toxicokinetics.
    Ings RM
    Xenobiotica; 1990 Nov; 20(11):1201-31. PubMed ID: 2275215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research tools for extrapolating the disposition and pharmacokinetics of nanomaterials from preclinical animals to humans.
    Valic MS; Zheng G
    Theranostics; 2019; 9(11):3365-3387. PubMed ID: 31244958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation.
    Thiel C; Schneckener S; Krauss M; Ghallab A; Hofmann U; Kanacher T; Zellmer S; Gebhardt R; Hengstler JG; Kuepfer L
    J Pharm Sci; 2015 Jan; 104(1):191-206. PubMed ID: 25393841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.
    Pierrillas PB; Henin E; Ogier J; Amiel M; Kraus-Berthier L; Chenel M; Bouzom F; Tod M
    Invest New Drugs; 2020 Dec; 38(6):1796-1806. PubMed ID: 32451663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a physiologically-based pharmacokinetic model of 2-phenoxyethanol and its metabolite phenoxyacetic acid in rats and humans to address toxicokinetic uncertainty in risk assessment.
    Troutman JA; Rick DL; Stuard SB; Fisher J; Bartels MJ
    Regul Toxicol Pharmacol; 2015 Nov; 73(2):530-43. PubMed ID: 26188115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBPK Modeling as an Alternative Method of Interspecies Extrapolation that Reduces the Use of Animals: A Systematic Review.
    Lancheros Porras KD; Alves IA; Novoa DMA
    Curr Med Chem; 2024; 31(1):102-126. PubMed ID: 37031391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches for predicting human pharmacokinetics using interspecies pharmacokinetic scaling.
    Kang HE; Lee MG
    Arch Pharm Res; 2011 Nov; 34(11):1779-88. PubMed ID: 22139680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
    Thompson CM; Sonawane B; Barton HA; DeWoskin RS; Lipscomb JC; Schlosser P; Chiu WA; Krishnan K
    J Toxicol Environ Health B Crit Rev; 2008 Aug; 11(7):519-47. PubMed ID: 18584453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
    Kirman CR; Sweeney LM; Corley R; Gargas ML
    Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interspecies comparisons in toxicology: the utility and futility of plasma concentrations of the test substance.
    Monro AM
    Regul Toxicol Pharmacol; 1990 Oct; 12(2):137-60. PubMed ID: 2259755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interspecies extrapolation in risk analysis.
    Travis CC
    Ann Ist Super Sanita; 1991; 27(4):581-93. PubMed ID: 1820730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Have physiologically-based pharmacokinetic models delivered?
    Edginton AN; Joshi G
    Expert Opin Drug Metab Toxicol; 2011 Aug; 7(8):929-34. PubMed ID: 21762039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.